1199796-29-6

Basic information

• Product Name: S-EMCA
• Synonyms: 6α-Ethyl-23(S)-Methylcholic acid;INT-777;S-EMCA;6alpha-Ethyl-23(S)-methylcholic acid
• CAS NO: 1199796-29-6
• Molecular Formula: C27H46O5
• Molecular Weight: 450.65114
• Mol File: 1199796-29-6.mol

Chemical Properties

• Melting Point: 150-152℃
• Boiling Point: 602.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.128±0.06 g/cm3(Predicted)
• PKA: 4.80±0.21(Predicted)
• CAS DataBase Reference: S-EMCA(CAS DataBase Reference)
• NIST Chemistry Reference: S-EMCA(1199796-29-6)
• EPA Substance Registry System: S-EMCA(1199796-29-6)

Safety Data

• Hazardous Substances Data: 1199796-29-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
S-EMCA is used as an inhibitor for the TGR5 receptor, which is a transmembrane G protein-coupled receptor expressed in brown adipose tissue and muscle and activated by bile acid. By inhibiting the TGR5 receptor, S-EMCA can potentially play a role in the development of treatments for various medical conditions related to this receptor's function.
Used in Research and Development:
S-EMCA can also be utilized in research and development settings to study the role of the TGR5 receptor in various biological processes and to develop new drugs targeting this receptor. Its unique chemical properties make it a valuable tool for understanding the receptor's function and potential therapeutic applications.

Upstream product

• 1227639-47-5 methyl 3α,7α,12α-trimethoxymethyloxy-6α-ethyl-5β-cholan-24-oate 
• 74-88-4 methyl iodide 

Relevant articles and documents

TGR5 MODULATORS AND METHODS OF USE THEROF

The invention relates to compounds of Formula A: or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.

Discovery of 6α-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity

In the framework of the design and development of TGR5 agonists, we reported that the introduction of a C23(S)-methyl group in the side chain of bile acids such as chenodeoxycholic acid (CDCA) and 6-ethylchenodeoxycholic acid (6-ECDCA, INT-747) affords selectivity for TGR5. Herein we report further lead optimization efforts that have led to the discovery of 6R-ethyl-23(S)- methylcholic acid (S-EMCA, INT-777) as a novel potent and selective TGR5 agonist with remarkable in vivo activity.